Invitrogen™ CD366 (TIM3) Monoclonal Antibody (RMT3-23), PE, eBioscience™, Invitrogen™

Rat Monoclonal Antibody

Description: The RMT3-23 monoclonal antibody reacts with mouse CD366 (TIM3), a Th1-specific cell surface protein. The RMT3-23 antibody reacts with CD366 protein expressed by both BALB/c and C57BL/6 strains of mice. CD366, a type I transmembrane protein, contains an immunoglobulin and a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. CD366 is expressed selectively by differentiated CD4^+Th1 and CD8^+Tc1 cells, but is absent on CD4^+Th2 and CD8^+Tc2 cells. Other hematopoietic cell types, including naive T cells, B cells, macrophages and dendritic cells, do not express CD366, at least at the protein level. CD366 expression is upregulated at a late stage of T cell differentiation on Th1 cells after 3 rounds of in vitro polarization suggesting a role for this molecule in the transport or effector function of Th1 cells rather than a contribution to T cell differentiation. In an experimental autoimmune encephalomyelitis (EAE) model, CD366 was shown to be expressed on most CD4^+ and CD8^+ T cells in the central nervous system at the onset of clinical signs of disease, while less than 2% of CD4^+ cells in the periphery expressed CD366 after immunization. RMT3-23 has been shown to have functional activity; blocks DC recognition of apoptotic cells and also induces autoantibody production. Applications Reported: The RMT3-23 antibody has been reported for use in flow cytometric analysis.